Letter | Published:

Chronic myeloproliferative neoplasms

Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1:97–105.

  2. 2.

    Link DC, Walter MJ. ‘CHIP’ping away at clonal hematopoiesis. Leukemia. 2016;30:1633–5.

  3. 3.

    Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54:1989–95.

  4. 4.

    Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372:601–12.

  5. 5.

    Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264–78.

  6. 6.

    Trifa AP, Banescu C, Tevet M, Bojan A, Dima D, Urian L, et al. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients. Br J Haematol. 2016;174:218–26.

  7. 7.

    Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016;128:1121–8.

  8. 8.

    Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006;43:531–3.

  9. 9.

    Godley LA. Inherited predisposition to acute myeloid leukemia. Semin Hematol. 2014;51:306–21.

  10. 10.

    Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87:1003–5.

  11. 11.

    Alvarez-Rodriguez L, Lopez-Hoyos M, Munoz-Cacho P, Martinez-Taboada VM. Aging is associated with circulating cytokine dysregulation. Cell Immunol. 2012;273:124–32.

  12. 12.

    Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, et al. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. 2018;97:109–21.

  13. 13.

    Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93:1474–84.

  14. 14.

    Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, et al. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia. 2015;29:869–76.

  15. 15.

    Mascarenhas J, Roper N, Chaurasia P, Hoffman R. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics. 2011;2:197–212.

Download references

Acknowledgements

This work was supported by NIH grants K08HL106576 (Oh) and T32HL007088 (Fowles). This work was also supported by a grant from the Longer Life Foundation (Oh). Additional support was provided by the Washington University Institute of Clinical and Translational Sciences grant UL1TR000448 from the National Center for Advancing Translational Sciences of NIH. Support for patient sample collection and processing was provided by NIH grant P01CA101937. Exome sequencing was performed at the McDonnell Genome Institute. Technical support was provided by the Alvin J. Siteman Cancer Center Tissue Procurement Core Facility, Flow Cytometry Core, and Immunomonitoring Laboratory, which are supported by NCI Cancer Center Support Grant P30CA91842. The Immunomonitoring Laboratory is also supported by the Bursky Center for Human Immunology and Immunotherapy Programs. The authors thank D. Bender for assistance with multiplex cytokine measurement and C. Miller for assistance with sequencing analysis.

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Stephen T. Oh.

Supplementary information

  1. Supplemental Methods

  2. Supplemental Figure S1

  3. Supplemental Figure S2

  4. Supplemental Figure S3

  5. Supplemental Figure S4

  6. Supplemental Table S1

  7. Supplemental Table S2

  8. Supplemental Table S3

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1